Kiromic BioPharma’s Journey at the Life Science Investor Forum
In the bustling heart of virtual investor gatherings, the OTC Markets’ Life Science Investor Forum sparkled with promises of breakthroughs and pioneering advancements. Among the lineup of visionary companies poised to take center stage was Kiromic BioPharma, a beacon of hope in the realm of immuno-oncology.
The Stage is Set
As the digital curtains parted on March 7th, 2024, anticipation swirled in the virtual air. Investors, analysts, and enthusiasts alike gathered in the online amphitheater, eager to witness the unfolding saga of medical innovation.
Presenting Kiromic BioPharma
representing the agenda for the Life Science Virtual Investor Forum on March 7th, 2024:
Please Visit : Virtual Investor Conferences
| Time (ET) | Company | Ticker(s) | Industry | Speakers | Moderator |
| 10:00 AM | Genflow Biosciences Plc | OTCQB: GENFF | LSE: GENF | Biotech – Longevity Therapeutics | Eric Leire, Founder & CEO | – |
| 10:30 AM | Lisata Therapeutics Inc. | Nasdaq: LSTA | Biopharma – Cellular Therapies | David Mazzo, President & CEO | – |
| 11:00 AM | Kiromic BioPharma, Inc. | OTCQB: KRBP | Biotherapeutics | Brian Hungerford, CFO | Brad Sorensen, CFA, Senior Equity Research Analyst |
| Leonardo Mirandola, CSO, iCOO | with Zacks Small-Cap Research | ||||
| Pietro Bersani, CEO | |||||
| 11:30 AM | Syra Health Corp. | NASDAQ: SYRA | Healthcare – Technology | Sandeep Allam, Executive Chairman & President | M. Marin, Senior Analyst with Zacks Small-Cap Research |
| 12:30 PM | Alpha Cognition Inc. | OTCQB: ACOGF | CSE: ACOG | Biopharma – Neurodegenerative Disorders | Lauren D’Angelo, COO | – |
| Michael McFadden, CEO & Director | |||||
| 1:00 PM | Achieve Life Sciences, Inc. | NASDAQ: ACHV | Pharmaceuticals – Smoking cessation and nicotine dependence | John Bencich, CEO | John Vandermosten, CFA, Senior Biotechnology Analyst with Zacks Small-Cap Research |
| 1:30 PM | Meridian Holdings, Inc./Dozie and Dozie’s Pharma | Pink: MRDH | Biotech – Intravenous Solutions | Anthony C. Dike, Chairman & CEO – Meridian Holdings, Inc. | – |
| Chidi Dozie, CEO & Pharmacy Director – Dozie & Dozie’s Pharmaceutical Limited | |||||
| Stanley I. Maduike, CCO – Dozie & Dozie’s Pharmaceutical Limited |
This table provides a structured overview of the Virtual Investor agenda, including the company names, ticker symbols, industry sectors, speakers, and moderators for each session
Presentation Schedule of Virtual Investor
| Time (ET) | Presentation | Ticker(s) |
| 10:00 AM | GenFlow Biosciences Plc | OTCQB: GENFF |
| 10:30 AM | Lisata Therapeutics, Inc. | Nasdaq: LSTA |
| 11:00 AM | Kiromic BioPharma, Inc. | OTCQB: KRBP |
| 11:30 AM | Syra Health Corp. | Nasdaq: SYRA |
| 12:30 PM | Alpha Cognition Inc. | OTCQB: ACOGF |
| 1:00 PM | Achieve Life Sciences, Inc. | NASDAQ: ACHV |
Register Now
The Fireside Chat: Unraveling Kiromic’s Innovation
Kiromic BioPharma stepped into the limelight, represented by its esteemed trio: Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford, and Chief Scientific Officer and Interim Operations Officer, Leonardo Mirandola, Ph.D. With a Fireside Chat format as their canvas, they embarked on a journey to illuminate the intricacies of Kiromic’s pioneering endeavors.
The Innovation Unveiled
At the heart of Kiromic’s narrative lay the DIAMOND® artificial intelligence (AI) 2.0 target discovery engine, a groundbreaking innovation poised to revolutionize the landscape of cell therapies. With unwavering dedication, Kiromic harnessed the power of AI to propel the development and commercialization of cell therapies, focusing intently on immuno-oncology.
During the Fireside Chat, the Kiromic team delved deeper into the mechanics of their proprietary DIAMOND® AI 2.0 target discovery engine. They showcased how this cutting-edge technology compresses the time and resources required for traditional drug development, offering a more efficient and cost-effective solution.
Expanding Horizons: The Significance of the Life Science Investor Forum
Beyond the digital confines of the forum, the significance of the Life Science Virtual Investor Forum resonated deeply within the medical and investment communities. It served as more than just a platform for companies to present to investors; it was a catalyst for collaboration, innovation, and progress.
By bringing together industry leaders, investors, and stakeholders, the forum fostered an environment where ideas flourished, partnerships formed, and breakthroughs emerged. It represented a crucial nexus where the forces of science, finance, and humanity converged in pursuit of a common goal: to conquer disease and alleviate human suffering.
Please Visit : Virtual Investor Conferences
A Brighter Tomorrow of Virtual Investor
As the curtains draw to a close on the Life Science Investor Forum, the echoes of innovation linger in the virtual ether. As investors and enthusiasts depart, they carry with them not just the promise of returns, but the assurance of a brighter tomorrow—a tomorrow where Kiromic BioPharma’s vision of a world free from the scourge of cancer stands within reach.
In the grand tapestry of human endeavor, Kiromic BioPharma has etched its mark—a mark of unwavering determination, boundless innovation, and relentless hope. And as the sun sets on March 7th, 2024, the world stands witness to the dawn of a new era—an era illuminated by the promise of a future where diseases bow before the might of human ingenuity.
